{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:12:58Z","timestamp":1792012378811,"version":"4.4.0"},"reference-count":118,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,1,30]],"date-time":"2019-01-30T00:00:00Z","timestamp":1548806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"DOI":"10.3389\/fmicb.2019.00080","type":"journal-article","created":{"date-parts":[[2019,1,29]],"date-time":"2019-01-29T23:15:14Z","timestamp":1548803714000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":453,"title":["Infections Caused by Carbapenem-Resistant Enterobacteriaceae: An Update on Therapeutic Options"],"prefix":"10.3389","volume":"10","author":[{"given":"Chau-Chyun","family":"Sheu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Ting","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shang-Yi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Hsu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Ren","family":"Hsueh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,1,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.1128\/JCM.00015-07","article-title":"Evaluation of methods to identify the Klebsiella pneumoniae carbapenemase in Enterobacteriaceae.","volume":"45","author":"Anderson","year":"2007","journal-title":"J. Clin. Microbiol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3109\/00365548.2013.861608","article-title":"Tigecycline therapy for infections due to carbapenemase-producing Klebsiella pneumoniae in critically ill patients.","volume":"46","author":"Balandin Moreno","year":"2014","journal-title":"Scand. J. Infect. Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.bmcl.2013.12.101","article-title":"Discovery of MK-7655, a beta-lactamase inhibitor for combination with Primaxin(R).","volume":"24","author":"Blizzard","year":"2014","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"B4","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1128\/AAC.01190-09","article-title":"Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.","volume":"54","author":"Bulik","year":"","journal-title":"Antimicrob. Agents Chemother."},{"key":"B5","doi-asserted-by":"publisher","first-page":"4112","DOI":"10.1128\/AAC.00026-10","article-title":"In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemase-producing Klebsiella pneumoniae.","volume":"54","author":"Bulik","year":"","journal-title":"Antimicrob. Agents Chemother."},{"key":"B6","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.1128\/AAC.01420-10","article-title":"Double-carbapenem therapy for carbapenemase-producing Klebsiella pneumoniae.","volume":"55","author":"Bulik","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"B7","doi-asserted-by":"publisher","first-page":"E23","DOI":"10.1111\/1469-0691.12070","article-title":"High rate of colistin resistance among patients with carbapenem-resistant Klebsiella pneumoniae infection accounts for an excess of mortality.","volume":"19","author":"Capone","year":"2013","journal-title":"Clin. Microbiol. Infect."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00313-18","article-title":"In vitro activity of plazomicin against Gram-negative and Gram-positive isolates collected from U.S. hospitals and comparative activities of aminoglycosides against carbapenem-resistant Enterobacteriaceae and isolates carrying carbapenemase genes.","volume":"62","author":"Castanheira","year":"","journal-title":"Antimicrob. Agents Chemother"},{"key":"B9","doi-asserted-by":"publisher","first-page":"3346","DOI":"10.1093\/jac\/dky344","article-title":"Activity of plazomicin compared with other aminoglycosides against isolates from European and adjacent countries, including Enterobacteriaceae molecularly characterized for aminoglycoside-modifying enzymes and other resistance mechanisms.","volume":"73","author":"Castanheira","year":"","journal-title":"J. Antimicrob. Chemother."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00567-17","article-title":"Meropenem-vaborbactam tested against contemporary Gram-negative isolates collected worldwide during 2014, including carbapenem-resistant, KPC-producing, multidrug-resistant, and extensively drug-Resistant Enterobacteriaceae.","volume":"61","author":"Castanheira","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"B11","doi-asserted-by":"publisher","first-page":"3509","DOI":"10.1128\/AAC.00163-15","article-title":"Ceftazidime-avibactam activity tested against Enterobacteriaceae isolates from U.S. hospitals (2011 to 2013) and characterization of beta-lactamase-producing strains.","volume":"59","author":"Castanheira","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"B12","doi-asserted-by":"publisher","first-page":"5454","DOI":"10.1128\/AAC.00711-16","article-title":"Effect of the beta-lactamase inhibitor vaborbactam combined with meropenem against serine carbapenemase-producing Enterobacteriaceae.","volume":"60","author":"Castanheira","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"B13","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ijid.2017.03.021","article-title":"Clinical efficacy of ceftazidime\/avibactam versus other active agents for the treatment of bacteremia due to carbapenemase-producing Enterobacteriaceae in hematologic patients.","volume":"59","author":"Cast\u00f3n","year":"2017","journal-title":"Int. J. Infect. Dis."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/jcm7080208","article-title":"Intravenous colistin monotherapy versus combination therapy against carbapenem-resistant Gram-negative bacteria infections: meta-analysis of randomized controlled trials.","volume":"7","author":"Cheng","year":"2018","journal-title":"J. Clin. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.1128\/AAC.01989-12","article-title":"Human simulated studies of aztreonam and aztreonam-avibactam to evaluate activity against challenging gram-negative organisms, including metallo-\u03b2-lactamase producers.","volume":"57","author":"Crandon","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1111\/j.1469-0691.2011.03553.x","article-title":"Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems?","volume":"17","author":"Daikos","year":"2011","journal-title":"Clin. Microbiol. Infect."},{"key":"B17","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/j.1469-0691.2006.01590.x","article-title":"Activity of imipenem against VIM-1 metallo-beta-lactamase-producing Klebsiella pneumoniae in the murine thigh infection model.","volume":"13","author":"Daikos","year":"2007","journal-title":"Clin. Microbiol. Infect."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1128\/AAC.00782-08","article-title":"Prospective observational study of the impact of VIM-1 metallo-beta-lactamase on the outcome of patients with Klebsiella pneumoniae bloodstream infections.","volume":"53","author":"Daikos","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1128\/AAC.02166-13","article-title":"Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems.","volume":"58","author":"Daikos","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES2014.19.9.20723","article-title":"Successful control of a hospital-wide outbreak of OXA-48 producing Enterobacteriaceae in the Netherlands, 2009 to 2011.","volume":"19","author":"Dautzenberg","year":"2014","journal-title":"Euro. Surveill."},{"key":"B21","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.ijantimicag.2017.05.006","article-title":"Recently approved antibacterials for methicillin-resistant Staphylococcus aureus (MRSA) and other Gram-positive pathogens: the shock of the new.","volume":"50","author":"David","year":"2017","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B22","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1128\/AAC.03042-15","article-title":"In vitro susceptibility to ceftazidime-avibactam of carbapenem-nonsusceptible Enterobacteriaceae isolates collected during the INFORM Global Surveillance Study (2012 to 2014).","volume":"60","author":"de Jonge","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-017-1769-z","article-title":"Double carbapenem as a rescue strategy for the treatment of severe carbapenemase-producing Klebsiella pneumoniae infections: a two-center, matched case-control study.","volume":"21","author":"De Pascale","year":"2017","journal-title":"Crit. Care"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1186\/cc13858","article-title":"High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria.","volume":"18","author":"De Pascale","year":"2014","journal-title":"Crit. Care"},{"key":"B25","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1080\/21505594.2016.1213476","article-title":"Meropenem for treating KPC-producing Klebsiella pneumoniae bloodstream infections: should we get to the PK\/PD root of the paradox?","volume":"8","author":"Del Bono","year":"2017","journal-title":"Virulence"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1007\/s40265-018-0966-7","article-title":"Meropenem\/vaborbactam: a review in complicated urinary tract infections.","volume":"78","author":"Dhillon","year":"2018","journal-title":"Drugs"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2253-13-13","article-title":"KPC-3 Klebsiella pneumoniae ST258 clone infection in postoperative abdominal surgery patients in an intensive care setting: analysis of a case series of 30 patients.","volume":"13","author":"Di Carlo","year":"2013","journal-title":"BMC Anesthesiol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1128\/AAC.01559-15","article-title":"Molecular characterization of carbapenem-nonsusceptible Enterobacterial isolates collected during a prospective interregional survey in France and susceptibility to the novel ceftazidime-avibactam and aztreonam-avibactam combinations.","volume":"60","author":"Dupont","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"B29","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1093\/jac\/dkn547","article-title":"Characterization of blaKPC-containing Klebsiella pneumoniae isolates detected in different institutions in the Eastern USA.","volume":"63","author":"Endimiani","year":"","journal-title":"J. Antimicrob. Chemother."},{"key":"B30","doi-asserted-by":"publisher","first-page":"4504","DOI":"10.1128\/AAC.00556-09","article-title":"ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates.","volume":"53","author":"Endimiani","year":"","journal-title":"Antimicrob. Agents Chemother."},{"key":"B31","doi-asserted-by":"publisher","first-page":"653","DOI":"10.2217\/fmb.11.49","article-title":"Therapeutic options for infections with Enterobacteriaceae producing carbapenem-hydrolyzing enzymes.","volume":"6","author":"Falagas","year":"2011","journal-title":"Future Microbiol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1128\/AAC.01222-13","article-title":"Antibiotic treatment of infections due to carbapenem-resistant Enterobacteriaceae: systematic evaluation of the available evidence.","volume":"58","author":"Falagas","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"B33","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1080\/17425255.2018.1434142","article-title":"Pharmacokinetic drug evaluation of avibactam + ceftazidime for the treatment of hospital-acquired pneumonia.","volume":"14","author":"Falcone","year":"2018","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.diagmicrobio.2017.04.015","article-title":"Synergistic activities of meropenem double and triple combinations against carbapenemase-producing Enterobacteriaceae.","volume":"88","author":"Fredborg","year":"2017","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000009961","article-title":"High-dose tigecycline for the treatment of nosocomial carbapenem-resistant Klebsiella pneumoniae bloodstream infections: a retrospective cohort study.","volume":"97","author":"Geng","year":"2018","journal-title":"Medicine"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.cmi.2015.08.001","article-title":"Risk factors for bloodstream infections due to colistin-resistant KPC-producing Klebsiella pneumoniae: results from a multicenter case-control-control study.","volume":"21","author":"Giacobbe","year":"2015","journal-title":"Clin. Microbiol. Infect."},{"key":"B37","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.ijantimicag.2017.08.019","article-title":"Effect of combination therapy containing a high-dose carbapenem on mortality in patients with carbapenem-resistant Klebsiella pneumoniae bloodstream infection.","volume":"51","author":"Giannella","year":"2018","journal-title":"Int. J. Antimicrob. Agents."},{"key":"B38","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1128\/AAC.01414-15","article-title":"Influence of colistin dose on global cure in patients with bacteremia due to carbapenem-resistant Gram-negative bacilli.","volume":"60","author":"Gibson","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"B39","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1586\/14787210.2016.1106940","article-title":"Infection control implications of heterogeneous resistance mechanisms in carbapenem-resistant Enterobacteriaceae (CRE).","volume":"14","author":"Goodman","year":"2016","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"B40","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/S1473-3099(17)30228-1","article-title":"Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study.","volume":"17","author":"Gutierrez-Gutierrez","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01968-17","article-title":"In vitro activity of the siderophore cephalosporin, cefiderocol, against carbapenem-nonsusceptible and multidrug-resistant isolates of Gram-negative bacilli collected worldwide in 2014 to 2016.","volume":"62","author":"Hackel","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"B42","doi-asserted-by":"publisher","first-page":"7396","DOI":"10.1128\/AAC.01405-16","article-title":"Siderophore cephalosporin cefiderocol utilizes ferric iron transporter systems for antibacterial activity against Pseudomonas aeruginosa.","volume":"60","author":"Ito","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1517\/13543784.2015.1095180","article-title":"Plazomicin: an investigational therapy for the treatment of urinary tract infections.","volume":"24","author":"Karaiskos","year":"2015","journal-title":"Expert Opin. Investig. Drugs"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00169-18","article-title":"In vitro activity of imipenem-relebactam against clinical isolates of Gram-negative bacilli isolated in hospital laboratories in the United States as part of the SMART 2016 program.","volume":"62","author":"Karlowsky","year":"2018","journal-title":"Antimicrob. Agents Chemother"},{"key":"B45","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1002\/phar.1636","article-title":"Infections caused by resistant Gram-negative bacteria: epidemiology and management.","volume":"35","author":"Kaye","year":"2015","journal-title":"Pharmacotherapy"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00449-17","article-title":"Multicenter study of outcomes with ceftazidime-avibactam in patients with carbapenem-resistant Enterobacteriaceae infections.","volume":"61","author":"King","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"B47","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/nrmicro2333","article-title":"How antibiotics kill bacteria: from targets to networks.","volume":"8","author":"Kohanski","year":"2010","journal-title":"Nat. Rev. Microbiol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.ijantimicag.2017.01.018","article-title":"Treating complicated carbapenem-resistant enterobacteriaceae infections with ceftazidime\/avibactam: a retrospective study with molecular strain characterisation.","volume":"49","author":"Krapp","year":"2017","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B49","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.jmii.2016.12.008","article-title":"Comparison of synergism between colistin, fosfomycin and tigecycline against extended-spectrum \u03b2-lactamase-producing Klebsiella pneumoniae isolates or with carbapenem resistance.","volume":"50","author":"Ku","year":"2017","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"B50","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S1473-3099(10)70143-2","article-title":"Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study.","volume":"10","author":"Kumarasamy","year":"2010","journal-title":"Lancet Infect. Dis."},{"key":"B51","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1093\/jac\/dkq278","article-title":"Activity of a novel aminoglycoside, ACHN-490, against clinical isolates of Escherichia coli and Klebsiella pneumoniae from New York City.","volume":"65","author":"Landman","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"B52","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jmii.2016.12.001","article-title":"Presence of multidrug-resistant organisms in the residents and environments of long-term care facilities in Taiwan.","volume":"50","author":"Lee","year":"2017","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"B53","doi-asserted-by":"publisher","first-page":"3840","DOI":"10.1128\/AAC.00436-16","article-title":"In vitro activity of eravacycline against carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii.","volume":"60","author":"Livermore","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"B54","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.ijantimicag.2011.01.012","article-title":"What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline.","volume":"37","author":"Livermore","year":"2011","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B55","doi-asserted-by":"publisher","first-page":"6234","DOI":"10.1128\/AAC.00633-16","article-title":"Phase 2, dose-ranging study of relebactam with imipenem-cilastatin in subjects with complicated intra-abdominal infection.","volume":"60","author":"Lucasti","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00406-17","article-title":"Mortality associated with bacteremia due to colistin-resistant Klebsiella pneumoniae with high-level meropenem resistance: importance of combination therapy without colistin and carbapenems.","volume":"61","author":"Machuca","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02243-16","article-title":"Can ceftazidime-avibactam and aztreonam overcome \u03b2-Lactam resistance conferred by metallo-\u03b2-Lactamases in Enterobacteriaceae?","volume":"61","author":"Marshall","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy150","article-title":"Association between carbapenem resistance and mortality among adult, hospitalized patients with serious infections due to Enterobacteriaceae: results of a systematic literature review and meta-analysis.","volume":"5","author":"Martin","year":"2018","journal-title":"Open Forum Infect. Dis."},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1177\/1060028018790573","article-title":"Critical review of double-carbapenem therapy for the treatment of carbapenemase-producing Klebsiella pneumoniae.","author":"Mashni","year":"2018","journal-title":"Ann. Pharmacother."},{"key":"B60","doi-asserted-by":"publisher","first-page":"S531","DOI":"10.1093\/ofid\/ofx163.1383","article-title":"Improved outcomes with plazomicin (PLZ) compared with colistin (CST) in patients with bloodstream infections (BSI) caused by carbapenem-resistant Enterobacteriaceae (CRE): results from the CARE Study.","volume":"4","author":"McKinnell","year":"2017","journal-title":"Open Forum Infect. Dis."},{"key":"B61","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/S1473-3099(13)70190-7","article-title":"Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases.","volume":"13","author":"Munoz-Price","year":"2013","journal-title":"Lancet Infect. Dis."},{"key":"B62","doi-asserted-by":"publisher","first-page":"E72","DOI":"10.1111\/1469-0691.12091","article-title":"Bacteraemia due to OXA-48-carbapenemase-producing Enterobacteriaceae: a major clinical challenge.","volume":"19","author":"Navarro-San Francisco","year":"2013","journal-title":"Clin. Microbiol. Infect."},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00989-17","article-title":"Resistance to ceftazidime-avibactam is due to transposition of KPC in a porin-deficient strain of Klebsiella pneumoniae with increased efflux activity.","volume":"61","author":"Nelson","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"B64","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.bjid.2014.12.004","article-title":"Efficacy of polymyxins in the treatment of carbapenem-resistant Enterobacteriaceae infections: a systematic review and meta-analysis.","volume":"19","author":"Ni","year":"2015","journal-title":"Braz. J. Infect. Dis."},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000003126","article-title":"Tigecycline treatment for carbapenem-resistant Enterobacteriaceae infections: a systematic review and meta-analysis.","volume":"95","author":"Ni","year":"2016","journal-title":"Medicine"},{"key":"B66","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jinf.2016.10.002","article-title":"Double-carbapenem regimen, alone or in combination with colistin, in the treatment of infections caused by carbapenem-resistant Klebsiella pneumoniae (CR-Kp).","volume":"74","author":"Oliva","year":"","journal-title":"J. Infect."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1093\/jac\/dkx084","article-title":"In vitro evaluation of different antimicrobial combinations against carbapenemase-producing Klebsiella pneumoniae: the activity of the double-carbapenem regimen is related to meropenem MIC value.","volume":"72","author":"Oliva","year":"","journal-title":"J. Antimicrob. Chemother."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1007\/s10096-017-2899-6","article-title":"Carbapenemase-producing Klebsiella pneumoniae bloodstream infection in critically ill patients: risk factors and predictors of mortality.","volume":"36","author":"Papadimitriou-Olivgeris","year":"2017","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"B69","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S1473-3099(18)30099-9","article-title":"Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial.","volume":"18","author":"Paul","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.2147\/IDR.S150447","article-title":"Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant Enterobacteriaceae.","volume":"11","author":"Petty","year":"2018","journal-title":"Infect. Drug Resist."},{"key":"B71","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.ijantimicag.2018.02.021","article-title":"In vitro activity of meropenem\/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem\/vaborbactam surveillance programme.","volume":"52","author":"Pfaller","year":"2018","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B72","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1093\/jac\/dkv294","article-title":"In vitro evaluation of dual carbapenem combinations against carbapenemase-producing Enterobacteriaceae.","volume":"71","author":"Poirel","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"B73","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1093\/jac\/dkm443","article-title":"Ongoing epidemic of blaVIM-1-positive Klebsiella pneumoniae in Athens, Greece: a prospective survey.","volume":"61","author":"Psichogiou","year":"2008","journal-title":"J. Antimicrob. Chemother."},{"key":"B74","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1093\/jac\/dkq431","article-title":"ST11, the dominant clone of KPC-producing Klebsiella pneumoniae in China.","volume":"66","author":"Qi","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"B75","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1128\/AAC.06268-11","article-title":"Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens.","volume":"56","author":"Qureshi","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00079-17","article-title":"Treatment of infections caused by extended-spectrum-beta-lactamase-, AmpC-, and carbapenemase-producing Enterobacteriaceae.","volume":"31","author":"Rodriguez-Bano","year":"2018","journal-title":"Clin. Microbiol. Rev."},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02163-17","article-title":"Pharmacokinetics, safety, and tolerability of cefiderocol, a novel siderophore cephalosporin for Gram-negative bacteria, in healthy subjects.","volume":"62","author":"Saisho","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"B78","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1093\/cid\/cis969","article-title":"Carbapenem-sparing antibiotic regimens for infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae in intensive care unit.","volume":"56","author":"Sbrana","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"B79","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1080\/14787210.2018.1436966","article-title":"Management of infections caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: current evidence and future prospects.","volume":"16","author":"Sheu","year":"2018","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02097-16","article-title":"Emergence of ceftazidime-avibactam resistance due to plasmid-borne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections.","volume":"61","author":"Shields","year":"","journal-title":"Antimicrob. Agents Chemother."},{"key":"B81","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1093\/cid\/ciw636","article-title":"Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections.","volume":"63","author":"Shields","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00883-17","article-title":"Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae Bacteremia.","volume":"61","author":"Shields","year":"","journal-title":"Antimicrob. Agents Chemother."},{"key":"B83","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1093\/jac\/dkx139","article-title":"Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem\/cilastatin plus relebactam with imipenem\/cilastatin alone in patients with complicated urinary tract infections.","volume":"72","author":"Sims","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"B84","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1001\/jamasurg.2016.4237","article-title":"Assessing the efficacy and safety of eravacycline vs ertapenem in complicated intra-abdominal infections in the investigating Gram-negative infections treated with eravacycline (IGNITE 1) trial: a randomized clinical trial.","volume":"152","author":"Solomkin","year":"2017","journal-title":"JAMA Surg."},{"key":"B85","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1007\/s10096-017-2936-5","article-title":"Double-carbapenem combination as salvage therapy for untreatable infections by KPC-2-producing Klebsiella pneumoniae.","volume":"36","author":"Souli","year":"2017","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"B86","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1093\/jac\/dkq470","article-title":"Efficacy of carbapenems against a metallo-beta-lactamase-producing Escherichia coli clinical isolate in a rabbit intra-abdominal abscess model.","volume":"66","author":"Souli","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"B87","doi-asserted-by":"publisher","first-page":"5548","DOI":"10.1128\/AAC.01288-13","article-title":"Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens.","volume":"57","author":"Sutcliffe","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"B88","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.ijantimicag.2015.12.021","article-title":"New drugs for the treatment of complicated intra-abdominal infections in the era of increasing antimicrobial resistance.","volume":"47","author":"Syue","year":"2016","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01140-18","article-title":"Phenotypic detection of carbapenemase-producing organisms from clinical isolates.","volume":"56","author":"Tamma","year":"2018","journal-title":"J. Clin. Microbiol."},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmii.2016.03.003","article-title":"Colistin-sparing regimens against Klebsiella pneumoniae carbapenemase-producing K. pneumoniae isolates: combination of tigecycline or doxycycline and gentamicin or amikacin.","author":"Tang","year":"2016","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01964-16","article-title":"Ceftazidime-avibactam as salvage therapy for infections caused by carbapenem-resistant organisms.","volume":"61","author":"Temkin","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"B92","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1080\/21505594.2016.1207834","article-title":"Role of newer and re-emerging older agents in the treatment of infections caused by carbapenem-resistant Enterobacteriaceae.","volume":"8","author":"Thaden","year":"2017","journal-title":"Virulence"},{"key":"B93","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.jmii.2016.08.022","article-title":"Risk factors and outcomes for the acquisition of carbapenem-resistant Gram-negative bacillus bacteremia: a retrospective propensity-matched case control study.","volume":"51","author":"Ting","year":"2018","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"B94","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.ijantimicag.2016.01.011","article-title":"Carbapenemase-producing Klebsiella pneumoniae bloodstream infections in neutropenic patients with haematological malignancies or aplastic anaemia: analysis of 50 cases.","volume":"47","author":"Tofas","year":"2016","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B95","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1002\/ajh.24489","article-title":"Bloodstream infections caused by Klebsiella pneumoniae in onco-hematological patients: clinical impact of carbapenem resistance in a multicentre prospective survey.","volume":"91","author":"Trecarichi","year":"2016","journal-title":"Am. J. Hematol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1080\/21505594.2017.1292196","article-title":"Therapeutic options for carbapenem-resistant Enterobacteriaceae infections.","volume":"8","author":"Trecarichi","year":"2017","journal-title":"Virulence"},{"key":"B97","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.jmii.2017.03.003","article-title":"The plasmid-mediated fosfomycin resistance determinants and synergy of fosfomycin and meropenem in carbapenem-resistant Klebsiella pneumoniae isolates in Taiwan.","volume":"50","author":"Tseng","year":"2017","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"B98","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1093\/jac\/dkv086","article-title":"Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study.","volume":"70","author":"Tumbarello","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"B99","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1093\/cid\/cis588","article-title":"Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy.","volume":"55","author":"Tumbarello","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"B100","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1128\/CMR.05035-11","article-title":"Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions.","volume":"25","author":"Tzouvelekis","year":"2012","journal-title":"Clin. Microbiol. Rev."},{"key":"B101","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1093\/cid\/cix783","article-title":"Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae.","volume":"66","author":"van Duin","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"B102","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1080\/23744235.2017.1350880","article-title":"Double carbapenem therapy (DCT) for bacteremia due to carbapenem-resistant Klebsiella pneumoniae (CRKP): from test tube to clinical practice.","volume":"49","author":"Venugopalan","year":"2017","journal-title":"Infect. Dis."},{"key":"B103","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1128\/AAC.02744-13","article-title":"In vitro activity of plazomicin against 5,015 Gram-negative and Gram-positive clinical isolates obtained from patients in canadian hospitals as part of the CANWARD study, 2011-2012.","volume":"58","author":"Walkty","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2013.00392","article-title":"Novel beta-lactamase inhibitors: a therapeutic hope against the scourge of multidrug resistance.","volume":"4","author":"Watkins","year":"2013","journal-title":"Front. Microbiol."},{"key":"B105","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.diagmicrobio.2017.05.009","article-title":"Synergistic activity of ceftazidime-avibactam and aztreonam against serine and metallo-\u03b2-lactamase-producing gram-negative pathogens.","volume":"88","author":"Wenzler","year":"2017","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1038\/nature.2017.21550","article-title":"The drug-resistant bacteria that pose the greatest health threats.","volume":"543","author":"Willyard","year":"2017","journal-title":"Nature"},{"key":"B107","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.ijantimicag.2013.02.015","article-title":"Impact of various conditions on the efficacy of dual carbapenem therapy against KPC-producing Klebsiella pneumoniae.","volume":"41","author":"Wiskirchen","year":"2013","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B108","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s40265-017-0725-1","article-title":"Novel beta-lactamase inhibitors: unlocking their potential in therapy.","volume":"77","author":"Wong","year":"2017","journal-title":"Drugs"},{"key":"B109","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.cmi.2017.09.001","article-title":"New agents for the treatment of infections with Gram-negative bacteria: restoring the miracle or false dawn?","volume":"23","author":"Wright","year":"2017","journal-title":"Clin. Microbiol. Infect."},{"key":"B110","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s40121-018-0214-1","article-title":"Effect and safety of meropenem-vaborbactam versus best-available therapy in patients with carbapenem-resistant Enterobacteriaceae Infections: the TANGO II randomized clinical trial.","volume":"7","author":"Wunderink","year":"2018","journal-title":"Infect. Dis. Ther."},{"key":"B111","doi-asserted-by":"publisher","first-page":"4433","DOI":"10.1128\/JCM.39.12.4433-4439.2001","article-title":"Outbreak of infection with multidrug-resistant Klebsiella pneumoniae carrying bla(IMP-8) in a university medical center in Taiwan.","volume":"39","author":"Yan","year":"2001","journal-title":"J. Clin. Microbiol."},{"key":"B112","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jmii.2016.01.003","article-title":"Enhanced efficacy of imipenem-colistin combination therapy against multiple-drug-resistant Enterobacter cloacae: in vitro activity and a Galleria mellonella model.","volume":"51","author":"Yang","year":"2018","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"B113","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1002\/phar.1622","article-title":"The beta-lactams strike back: ceftazidime-avibactam.","volume":"35","author":"Zasowski","year":"2015","journal-title":"Pharmacotherapy"},{"key":"B114","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1080\/14787210.2017.1316193","article-title":"Aminoglycosides against carbapenem-resistant Enterobacteriaceae in the critically ill: the pitfalls of aminoglycoside susceptibility.","volume":"15","author":"Zavascki","year":"2017","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"B115","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s40265-016-0545-8","article-title":"Review of eravacycline, a novel fluorocycline antibacterial agent.","volume":"76","author":"Zhanel","year":"2016","journal-title":"Drugs"},{"key":"B116","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s40265-017-0851-9","article-title":"Imipenem-relebactam and meropenem-vaborbactam: two novel carbapenem-beta-lactamase inhibitor combinations.","volume":"78","author":"Zhanel","year":"2018","journal-title":"Drugs"},{"key":"B117","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/ja.2016.73","article-title":"In vitro susceptibility of beta-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE) to eravacycline.","volume":"69","author":"Zhang","year":"2016","journal-title":"J. Antibiot."},{"key":"B118","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/jac\/dkw377","article-title":"Polymyxin monotherapy or in combination against carbapenem-resistant bacteria: systematic review and meta-analysis.","volume":"72","author":"Zusman","year":"2017","journal-title":"J. Antimicrob. Chemother."}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmicb.2019.00080\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,29]],"date-time":"2019-01-29T23:15:15Z","timestamp":1548803715000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmicb.2019.00080\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,30]]},"references-count":118,"alternative-id":["10.3389\/fmicb.2019.00080"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2019.00080","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,30]]},"article-number":"80"}}